Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
30th Annual Meeting of the ISCP
Author(s): Maria Victoria Luis Valle , Adela Castro Garcia , Diego De la Eranueva Calvo , et al Added: 1 month ago

Prevention & Chronic Conditions

Guidelines & Statements
Author(s): Finn Gustafsson Added: 2 years ago
HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two… View more

Anticoagulation

Heart Failure
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 1 year ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention
Antiplatelet Treatment with Dual Pathway Inhibition
Author(s): Tobias Geisler Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
AHA 25: TUXEDO-2: Ticagrelor vs Prasugrel in Diabetic PCI
Author(s): Sripal Bangalore , Harriette Van Spall Added: 6 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) was joined by the TUXEDO-2 Principal Investigator, Dr Sripal Bangalore to present the findings of this late-breaking randomized trial comparing ticagrelor versus prasugrel in patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)… View more

Anticoagulation

Intervention
Sex Influences DAPT De-escalation Outcomes Post-PCI
Added: 1 month ago Source:  Interventional Cardiology
Mirjam Boros, Radcliffe CardiologyDe-escalation of dual antiplatelet therapy (DAPT) is a strategy used to improve outcomes after percutaneous coronary intervention (PCI).¹˒² However, the impact of patient sex on the safety and efficacy of these strategies has been unclear. A new network meta-analysis published in the European Heart Journal has investigated these potential differences… View more

Intervention

Anticoagulation
The OCEAN Trial and the Expanding Indications for AF Ablation
Author(s): Jaspal Singh Gill , Viral Sagar , Mark M Gallagher Added: 3 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Research Area(s) / Expertise: Job title: Adjunct Professor of Pharmacology
ESC 25: 4 Heart Failure Trials That Will Change My Practice
Author(s): Michelle Kittleson Added: 9 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial… View more

Anticoagulation

Heart Failure
Obesity, Pharmacokinetics and Cardiovascular Drugs
Author(s): Dario Pitocco , Martina Cortelletti , Giovanna Petrucci , et al Added: 5 days ago

Prevention & Chronic Conditions

Anticoagulation